{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:29:46Z","timestamp":1792225786946,"version":"4.4.0"},"reference-count":100,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T00:00:00Z","timestamp":1671667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>In the category of mature B-cell neoplasms, splenic B-cell lymphoma and leukemia were clearly identified and include four distinct entities: hairy cell leukemia (HCL), splenic marginal zone lymphoma (SMZL), splenic diffuse red pulp lymphoma (SDRPL) and the new entity named splenic B-cell lymphoma\/leukemia with prominent nucleoli (SBLPN). The BRAF<jats:sup>V600E<\/jats:sup> mutation is detected in nearly all HCL cases and offers a possibility of targeted therapy. BRAF inhibitors (BRAFi) represent effective and promising therapeutic approaches in patients with relapsed\/refractory HCL. Vemurafenib and dabrafenib were assessed in clinical trials. The BRAF<jats:sup>V600E<\/jats:sup> mutation is missing in SDRPL and SBLPN: mitogen-activated protein kinase 1 (MAP2K1) mutations were found in 40% of SBLPN and VH4-34+ HCL patients, making possible to use MEK inhibitors (MEKi) such as trametinib, cobimetinib or binimetinib in monotherapy or associated with BRAFi. Other mutations may be associated and other signaling pathways involved, including the B-cell receptor signaling (BCR), cell cycle, epigenetic regulation and\/or chromatin remodeling. In SDRPL, cyclin D3 (CCND3) mutations were found in 24% of patients, offering the possibility of using cell cycle inhibitors. Even if new emerging drugs, particularly those involved in the epigenetic regulation, have recently been added to the therapeutic armamentarium in HCL and HCL-like disorders, purine nucleoside analogs more and more associated with anti-CD20 monoclonal antibodies, are still used in the frontline setting. Thanks to the recent discoveries in genetics and signaling pathways in HCL and HCL-like disorders, new targeted therapies have been developed, have proven their efficacy and safety in several clinical trials and become essential in real life: BRAFi, MEKi, Bruton Tyrosine Kinase inhibitors (BTKi) and anti-CD22 immunotoxins. New other drugs emerged and have to be assessed in the future. In this article, we will discuss the main mutations identified in HCL and HCL-like disorders and the signaling pathways potentially involved in the pathogenesis of the different hairy cell disorders. We will discuss the results of the recent clinical trials, which will help us to propose an algorithm useful in clinical practice and we will highlight the different new drugs that may be used in the near future.<\/jats:p>","DOI":"10.3389\/fonc.2022.1068981","type":"journal-article","created":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T12:43:56Z","timestamp":1671713036000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Novel targeted treatments in hairy cell leukemia and other hairy cell-like disorders"],"prefix":"10.3389","volume":"12","author":[{"given":"Elsa","family":"Maitre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Paillassa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Troussard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: Lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21357","article-title":"US Lymphoid malignancy statistics by world health organization subtypes: 2016 US lymphoid malignancy statistics by world health organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1014209","article-title":"BRAF mutations in hairy-cell leukemia","volume":"364","author":"Tiacci","year":"2011","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol28050297","article-title":"New insights into the biology and diagnosis of splenic marginal zone lymphomas","volume":"28","author":"Donzel","year":"2021","journal-title":"Curr Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-098848","article-title":"Splenic red pulp lymphoma with numerous basophilic villous lymphocytes: a distinct clinicopathologic and molecular entity","volume":"111","author":"Traverse-Glehen","year":"2008","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2021.1908121","article-title":"Diagnostic and therapeutic challenges in hairy cell leukemia-variant: where are we in 2021","volume":"14","author":"Matutes","year":"2021","journal-title":"Expert Rev Hematol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/ng.2828","article-title":"High prevalence of MAP2K1 mutations in variant and IGHV4-34\u2013expressing hairy-cell leukemias","volume":"46","author":"Waterfall","year":"2013","journal-title":"Nat Genet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-04-643361","article-title":"Recurrent CDKN1B (p27) mutations in hairy cell leukemia","volume":"126","author":"Dietrich","year":"2015","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e0149162","DOI":"10.1371\/journal.pone.0149162","article-title":"Exome sequencing in classic hairy cell leukaemia reveals widespread variation in acquired somatic mutations between individual tumours apart from the signature BRAF V(600)E lesion","volume":"11","author":"Weston-Bell","year":"2016","journal-title":"PLoS One"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-01-765107","article-title":"Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations","volume":"130","author":"Durham","year":"2017","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14081904","article-title":"Deciphering genetic alterations of hairy cell leukemia and hairy cell leukemia-like disorders in 98 patients","volume":"14","author":"Maitre","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/LEU.2012.163","article-title":"Hairy cell leukemia cell lines expressing annexin A1 and displaying b-cell receptor signals characteristic of primary tumor cells lack the signature BRAF mutation to reveal unrepresentative origins","volume":"27","author":"Weston-Bell","year":"2013","journal-title":"Leukemia"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/FONC.2021.598319\/BIBTEX","article-title":"In vitro sensitivity to venetoclax and microenvironment protection in hairy cell leukemia","volume":"11","author":"Vereertbrugghen","year":"2021","journal-title":"Front Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/ng1054","article-title":"High frequency of BRAF mutations in nevi","volume":"33","author":"Pollock","year":"2002","journal-title":"Nat Genet"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12735","article-title":"Alternative BRAF mutations in BRAF V600E-negative hairy cell leukaemias","volume":"165","author":"Tschernitz","year":"2014","journal-title":"Br J Haematol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-01-201731","article-title":"VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy","volume":"114","author":"Arons","year":"2009","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-212449","article-title":"Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior","volume":"114","author":"Forconi","year":"2009","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.160192","article-title":"Exome sequencing identifies recurrent BCOR gene alterations and the absence of KLF2, TNFAIP3 and MYD88 mutations in splenic diffuse red pulp small b-cell lymphoma","volume":"102","author":"Jallades","year":"2017","journal-title":"Haematologica"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-11-751024","article-title":"Splenic diffuse red pulp small b-cell lymphoma displays increased expression of cyclin D3 and recurrent CCND3 mutations","volume":"129","author":"Curiel-Olmo","year":"2017","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1097\/PAS.0000000000000523","article-title":"NOTCH1, TP53, and MAP2K1 mutations in splenic diffuse red pulp small b-cell lymphoma are associated with progressive disease","volume":"40","author":"Martinez","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.078071","article-title":"Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia","volume":"98","author":"Tiacci","year":"2013","journal-title":"Haematologica"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2031298","article-title":"emurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia","volume":"384","author":"Tiacci","year":"2021","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-603100","article-title":"BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity","volume":"125","author":"Pettirossi","year":"2015","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-07-418434","article-title":"BRAF V600E mutation in hairy cell leukemia: from bench to bedside","volume":"128","author":"Falini","year":"2016","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/S41375-021-01210-8","article-title":"Safety and efficacy of the BRAF inhibitor dabrafenib in relapsed or refractory hairy cell leukemia: A pilot phase-2 clinical trial","volume":"35","author":"Tiacci","year":"2021","journal-title":"Leukemia"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-225326","article-title":"The microenvironment in mature b-cell malignancies: A target for new treatment strategies","volume":"114","author":"Burger","year":"2009","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2013.07.002","article-title":"B cell receptor signaling in chronic lymphocytic leukemia","volume":"34","author":"Burger","year":"2013","journal-title":"Trends Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated waldenstr\u00f6m\u2019s macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large b cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2016-10-747345","article-title":"Targeting bruton tyrosine kinase with ibrutinib in relapsed\/refractory marginal zone lymphoma","volume":"129","author":"Noy","year":"2017","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12867","article-title":"The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: A new therapeutic approach","volume":"166","author":"Sivina","year":"2014","journal-title":"Br J Haematol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-386417","article-title":"The bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo","volume":"119","author":"Ponader","year":"2012","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0086556","article-title":"Variant b cell receptor isotype functions differ in hairy cell leukemia with mutated BRAF and IGHV genes","volume":"9","author":"Weston-Bell","year":"2014","journal-title":"PLoS One"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402107","article-title":"Differential expression of chemokine receptors in b cell malignancies","volume":"15","author":"D\u00fcrig","year":"2001","journal-title":"Leukemia"},{"key":"B36","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1084\/JEM.20031175","article-title":"Gene expression profiling of hairy cell leukemia reveals a phenotype related to memory b cells with altered expression of chemokine and adhesion receptors","volume":"199","author":"Basso","year":"2004","journal-title":"J Exp Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1080\/10428190410001723449","article-title":"Chemokine receptor expression in b-cell lymphoproliferative disorders","volume":"45","author":"Wong","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2015.09.006","article-title":"The importance of the tissue microenvironment in hairy cell leukemia","volume":"28","author":"Sivina","year":"2015","journal-title":"Best Pract Res Clin Haematol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"20406207221090886","DOI":"10.1177\/20406207221090886","article-title":"Updates in hairy cell leukemia (HCL) and variant-type HCL (HCL-v): Rationale for targeted treatments with a focus on ibrutinib","volume":"13","author":"Paillassa","year":"2022","journal-title":"Ther Adv Hematol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/J.IMMUNI.2006.11.012","article-title":"Bruton\u2019s tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled b cell migration and homing","volume":"26","author":"de Gorter","year":"2007","journal-title":"Immunity"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2011-11-390989","article-title":"The clinically active BTK inhibitor PCI-32765 targets b-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia","volume":"119","author":"De Rooij","year":"2012","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1093\/EMBOJ\/CDF588","article-title":"Inducible gene deletion reveals different roles for b-raf and raf-1 in b-cell antigen receptor signalling","volume":"21","author":"Brummer","year":"2002","journal-title":"EMBO J"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1888","article-title":"Evolving concepts in the pathogenesis of hairy-cell leukaemia","volume":"6","author":"Tiacci","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2017.0165","article-title":"Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology","volume":"15","author":"Weirda","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2140-y","article-title":"Recommendations of the SFH (French society of haematology) for the diagnosis, treatment and follow-up of hairy cell leukaemia","volume":"93","author":"Cornet","year":"2014","journal-title":"Ann Hematol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41408-020-0328-z","article-title":"Analysis of a cohort of 279 patients with hairy-cell leukemia (HCL): 10 years of follow-up","volume":"10","author":"Paillassa","year":"2020","journal-title":"Blood Cancer J"},{"key":"B47","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/S41408-022-00702-9","article-title":"Long-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian study","volume":"12","author":"Pagano","year":"2022","journal-title":"Blood Cancer J"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14129","article-title":"Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial","volume":"174","author":"Chihara","year":"2016","journal-title":"Br J Haematol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1200\/JCO.19.02250","article-title":"Randomized phase II study of first-line cladribine with concurrent or delayed rituximab in patients with hairy cell leukemia","volume":"38","author":"Chihara","year":"2020","journal-title":"J Clin Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1182\/BLOODADVANCES.2021005039","article-title":"Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant","volume":"5","author":"Chihara","year":"2021","journal-title":"Blood Adv"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.3109\/10428194.2011.562575","article-title":"Response of hairy cell leukemia to bendamustine","volume":"52","author":"Kreitman","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-1848","article-title":"Bendamustine and rituximab in relapsed and refractory hairy cell leukemia","volume":"19","author":"Burotto","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.21304","article-title":"Bendamustine plus rituximab is an effective first-line treatment in hairy cell leukemia variant: A report of three cases","volume":"8","author":"Visentin","year":"2017","journal-title":"Oncotarget"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000024457","article-title":"Long-term follow-up after rituximab plus bendamustine in a patient with relapsed or refractory hairy cell leukemia variant: A case report","volume":"100","author":"Imoto","year":"2021","journal-title":"Med (Baltimore)"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-3219-z","article-title":"MRD-negative complete remission in relapsed refractory hairy cell leukemia with bendamustine and obinutuzumab","volume":"97","author":"Sadeghi","year":"2018","journal-title":"Ann Hematol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25243","article-title":"Hairy cell leukemia: Evaluation of the long-term outcome in 121 patients","volume":"116","author":"Zinzani","year":"2010","journal-title":"Cancer"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.4.1160","article-title":"Second malignancies in patients with hairy cell leukemia in British Columbia: A 20-year experience","volume":"92","author":"Au","year":"1998","journal-title":"Blood"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.6.1918","article-title":"Long-term follow-up of patients with hairy cell leukemia after cladribine treatment","volume":"92","author":"Saven","year":"1998","journal-title":"Blood"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.05.093","article-title":"Extended follow-up of patients with hairy cell leukemia after treatment with cladribine","volume":"21","author":"Goodman","year":"2003","journal-title":"J Clin Oncol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1517\/14740330903427951","article-title":"Inherent and iatrogenic immune defects in hairy cell leukemia: Revisited","volume":"9","author":"Dasanu","year":"2010","journal-title":"Expert Opin Drug Saf"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1002\/CNR2.1495","article-title":"Patients with relapsed\/refractory hairy-cell leukemia","volume":"5","author":"Paillassa","year":"2021","journal-title":"Cancer Rep (Hoboken NJ)"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V83.10.2906.2906","article-title":"2-chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia","volume":"83","author":"Seymour","year":"1994","journal-title":"Blood"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2400513","article-title":"Response duration and recovery of CD4+ lymphocytes following deoxycoformycin in interferon-alpha-resistant hairy cell leukemia: 7-year follow-up","volume":"11","author":"Seymour","year":"1997","journal-title":"Leukemia"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1046\/j.0007-1048.2001.03318.x","article-title":"Severe decrease in peripheral blood dendritic cells in hairy cell leukaemia","volume":"116","author":"Bourguin-Plonquet","year":"2002","journal-title":"Br J Haematol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1080\/10428199909169620","article-title":"Five years follow-up after 2-chloro deoxyadenosine treatment in thirty patients with hairy cell leukemia: Evaluation of minimal residual disease and CD4+ lymphocytopenia after treatment","volume":"35","author":"Bastie","year":"1999","journal-title":"Leuk Lymphoma"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V83.12.3672.3672","article-title":"Flow cytometry of blood and bone marrow cells from patients with hairy cell leukemia: Phenotype of hairy cells and lymphocyte subsets after treatment with 2-chlorodeoxyadenosine","volume":"83","author":"Juliusson","year":"1994","journal-title":"Blood"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1159\/000203677","article-title":"T Cells and natural killer cells after treatment of hairy cell leukaemia with 2-chlorodeoxyadenosine","volume":"97","author":"Schirmer","year":"1997","journal-title":"Acta Haematol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/j.1600-0609.1994.tb01279.x","article-title":"Rapid restoration of natural killer activity following treatment with 2-chlorodeoxyadenosine in 22 patients with hairy-cell leukemia","volume":"52","author":"Lauria","year":"2009","journal-title":"Eur J Haematol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506583","article-title":"Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia","volume":"373","author":"Tiacci","year":"2015","journal-title":"N Engl J Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD.2022016183","article-title":"Long term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy","author":"Handa","year":"2022","journal-title":"Blood"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-680074","article-title":"BRAF inhibition in hairy cell leukemia with low-dose vemurafenib","volume":"127","author":"Dietrich","year":"2016","journal-title":"Blood"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25474","article-title":"Low-dose vemurafenib in hairy cell leukemia patients with active infection","volume":"94","author":"Bohn","year":"2019","journal-title":"Am J Hematol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/S41375-021-01257-7","article-title":"Hairy cell leukemia and COVID-19 adaptation of treatment guidelines","volume":"35","author":"Grever","year":"2021","journal-title":"Leukemia"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD.2021013658","article-title":"Dabrafenib plus trametinib in patients with relapsed\/refractory BRAF V600E mutation-positive hairy cell leukemia","author":"Kreitman","year":"2022","journal-title":"Blood"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2031298","article-title":"Vemurafenib plus rituximab in refractory or relapsed hairy-cell leukemia","volume":"384","author":"Tiacci","year":"2021","journal-title":"N Engl J Med"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009688","article-title":"Phase 2 study of ibrutinib in classic and variant hairy cell leukemia","volume":"137","author":"Rogers","year":"2021","journal-title":"Blood"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA1400029\/SUPPL_FILE\/NEJMOA1400029_DISCLOSURES.PDF","article-title":"Resistance mechanisms for the bruton\u2019s tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N Engl J Med"},{"key":"B79","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.1182\/BLOOD-2014-02-548610","article-title":"Ibrutinib inhibits BCR and NF-\u03baB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL","volume":"123","author":"Herman","year":"2014","journal-title":"Blood"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1512710\/SUPPL_FILE\/ILAL_A_1512710_SM8890.PDF","article-title":"Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib","volume":"60","author":"Barrientos","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2016.1239262","article-title":"Ibrutinib for relapsed refractory hairy cell leukemia variant","volume":"58","author":"Bohn","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1002\/HON.2810","article-title":"Ibrutinib in relapsed hairy cell leukemia variant: A case report and review of the literature","volume":"38","author":"Visentin","year":"2020","journal-title":"Hematol Oncol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia","volume":"374","author":"Byrd","year":"2016","journal-title":"N Engl J Med"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.2147\/JEP.S265284","article-title":"The role of BTK inhibition in the treatment of chronic lymphocytic leukemia: A clinical view","volume":"13","author":"Tambaro","year":"2021","journal-title":"J Exp Pharmacol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N Engl J Med"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2020.1737010","article-title":"Approved and emerging PI3K inhibitors for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma","volume":"21","author":"Kienle","year":"2020","journal-title":"Expert Opin Pharmacother"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1111\/J.1600-065X.2009.00801.X","article-title":"CD22 and siglec-G: B-cell inhibitory receptors with distinct functions","volume":"230","author":"Nitschke","year":"2009","journal-title":"Immunol Rev"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000507","article-title":"Moxetumomab pasudotox for hairy cell leukemia: Preclinical development to FDA approval","volume":"3","author":"Lin","year":"2019","journal-title":"Blood Adv"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0210-1","article-title":"Moxetumomab pasudotox in relapsed\/refractory hairy cell leukemia","volume":"32","author":"Kreitman","year":"2018","journal-title":"Leukemia"},{"key":"B90","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/S13045-020-01004-Y","article-title":"Moxetumomab pasudotox in heavily pre-treated patients with relapsed\/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial","volume":"14","author":"Kreitman","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.1756","article-title":"Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia","volume":"30","author":"Kreitman","year":"2012","journal-title":"J Clin Oncol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-803072","article-title":"Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up","volume":"131","author":"Kreitman","year":"2018","journal-title":"Blood"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2012971\/SUPPL_FILE\/NEJMOA2012971_DATA-SHARING.PDF","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30012-8","article-title":"Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA1815281\/SUPPL_FILE\/NEJMOA1815281_DATA-SHARING.PDF","article-title":"Venetoclax and obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N Engl J Med"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA1900574\/SUPPL_FILE\/NEJMOA1900574_DATA-SHARING.PDF","article-title":"Ibrutinib and venetoclax for first-line treatment of CLL","volume":"380","author":"Jain","year":"2019","journal-title":"N Engl J Med"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1002\/AJH.25264","article-title":"Biclonal IGHV-4-34 hairy cell leukemia variant and CLL - successful treatment with ibrutinib and venetoclax","volume":"93","author":"Jain","year":"2018","journal-title":"Am J Hematol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.731599","article-title":"Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies","volume":"54","author":"Daneshmanesh","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD.2021014760","article-title":"ROR1: an orphan becomes apparent","volume":"140","author":"Kipps","year":"2022","journal-title":"Blood"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1068981\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T12:44:00Z","timestamp":1671713040000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1068981\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,22]]},"references-count":100,"alternative-id":["10.3389\/fonc.2022.1068981"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.1068981","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,22]]},"article-number":"1068981"}}